

Funded Core Studies¹
(As of July 1, 2017)

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W1	CT core analytes on 6% subsample; Clinic CBC tests: Semi-annual core analytes on QC pools A and B	Complete	CT Controls:3800 *B, Y1, Y3, Y6 on 6% Blood Subsample	Citrate 1ml: FVII:C; Fibrinogen; FVII Ag EDTA 1ml: Trig; Cholesterol; Lp(a); LDLC; HDL2; HDL3; HDLC EDTA .25ml: Trig; Creatinine; Glucose; Cholesterol; LDLC; CRP; HDLC; Insulin Serum 1ml: Tocopherol, alpha; Cryptoxan, beta; Glucose; Lycopene; Carotene, beta; Retinol; Tocopherol, gamma; Insulin; Lutein+Zeaxanthin; Carotene, alpha Serum .25ml: Trig; CRP; Cholesterol; Glucose; HDLC; LDLC; Insulin; Creatinine Whole 2ml: PLT; HCT; Hemoglobin; WBC	204, 210, 222, 240, 273, 345, 347, 350, 447, 448, 449, 520, 521, 524, 866, 3202, 3204
W2	OS-measurement precision study (OS-MPS)	Complete	OS Controls:800 *B, 3 month	Citrate 1ml: FVII Ag; FVII:C; Fibrinogen EDTA 1ml: HDL3; Lp(a); Cholesterol; LDLC; Trig; HDLC; HDL2 Serum 1ml: Carotene, alpha; Insulin; Glucose; Lutein+Zeaxanthin; Tocopherol, alpha; Lycopene; Cryptoxan, beta; Tocopherol, gamma; Retinol; Carotene, beta	442, 524, 2828, 3202
W4	National validation and quality control assurance of vitamin D absorption from CaD tablets for WHI	Complete	CaD Controls:448 *Y3	Serum 1ml: Vit D 25-OH	
W5	Correlates of endogenous sex hormone concentrations in DM trial	Complete	DM Controls:300 *150 DM Intervention + 150 DM controls at B and Y1	Serum 3ml: Albumin; SHBG; Estradiol (E2); Estrone sulfate; Progesterone; Estradiol, bioavailable; Androstenedione; DHT; DHES; Estradiol, bioavail (%); Prolactin; Testosterone; DHEA; Estrone (E1)	20, 280, 1218, 2447

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W6	HT CVD Biomarkers: study of CHD, Stroke and VTE - Phase I	Complete	HT CHD:402 Stroke:272 VTE:223 Controls:877 *B, Y1	Citrate 1ml: Protein C; ATIII; F1+2; vWF; CRP; TAFI; Protein S Free; Fibrinogen; FVIII Activity; Prothrombin Ag; PAP; D-dimers; FIX Conc; PAI-1 Ag; Protein S Total DNA 3ug: ESR1; ESR2; GP3A-P1A; GPIIb; ITGA2807CT DNA 3ug: PAI-1; PROT; FXIII val34leu; FV Leiden; PRO2; FV-HR2; MTHFR EDTA .25ml: NMR Lipids EDTA 1ml: Trig; LDLC; HDL2; Homocysteine; IL-6; E-Selectin; Lipo-particles; HDL3; Lp(a); Cholesterol; HDLC Serum 1ml: MMP-9	204, 210, 222, 273, 345, 347, 350, 380, 429, 445, 462, 526, 854, 866, 972, 2048, 2432, 3271
W7	Genome-wide scan on breast cancer, CHD, and stroke	Complete	General population Breast Cancer:2145 CHD:2119 Stroke:2215 Controls:6479	DNA 2ug: Pooled GWAS	1104, 1653
W8	Nutritional biomarkers study (NBS)	Complete	DM	24hr Urine 1.85ml: PABARCVR; PABARCVRH; PABACMP; 24 hr Urine Volume; Urine N g/L; Urine N g/day; Paba mg/L (hplc); PABA; Paba mg/24hr (hplc); PABA24; PABACMPH; 24 hr urine volume, nitrogen g/day, nitrogen g/L, sodium, potasium; Paba mg/L (colorimetric and HPLC); Paba mg/24 hr (colorimetric); Paba completeness (colorimetric and HPLC); Paba recovery (colorimetric and HPLC); 24hr Urine 4ml: Urinary potassium; Urinary Sodium DLW Spot Urine 4ml: Fluid; Total Body Water; TEE-USRQ; TEE-INTVRQ; EE3/5; O18-SU3; DE-SU4; DE-SU5; DE-SU6; O18CONST; RCO2-3/5; Fat-free mass; r-H2O; % Fat; O18- SU4; DSRATIO; Nd; RCO2-4/6; TEE- CONRQ; DE-SU3; H2CONST; No; EE4/6; O18-SU5; O18-SU6; LOT; NBS Spot Urine 4 ml: %Fat; DE-SU3; DE-SU4; DE-SU5; DE- SU6; EE3/5; EE4/6; Fat-free mass; Fluid; H2CONST; Internal check DSRatio; LOT; Nd;	464, 624, 646, 708, 831, 941, 945, 1903, 2022, 2106, 2397

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
				No; O18-SU3; O18-SU4; O18-SU5; O18-SU6; O18CONST; RCO2-3/5; RCO2-4/6; TEE-CONRQ RQ Control group (38.1/44.7/17.2 %E from F/C/P); TEE-INTVRQ Intervention (29.8/52.7/17.5 %E from F/C/P); TEE-USRQ RQ assumed general US (34/47/18 %E F/C/P); Total Body Water; r-H2O EDTA 1ml: Serum .2ml: Carotene, alpha; Carotene, beta; Cholesterol; Tocopherol, gamma; Folate; Tocopherol, alpha	
W9	Biological markers of the effect of HT on risk of fractures in the Women's Health Initiative clinical trial	Complete	HT Fracture - Hip:750 Controls:750 *Cases=248 hip fractures + 502 non-spine fractures	Serum .65ml: Estradiol, free; SHBG; Estradiol (E2); Estradiol, bioavailable	433, 1218, 1579, 2447, 3231
W10	Biological markers of the effect of HT on risk of breast cancer in the Women's Health Initiative clinical trial	Complete	HT Breast Cancer:755 Controls:755 *498 E+P and 260 E-Along cases through Sept 2005; B+Y1	Serum .95ml: Testosterone, free; Estradiol, bioavailable; Estrone (E1); Progesterone; Estradiol, free; SHBG; Testosterone; Testosterone, bioavail; Estradiol (E2); Estrone sulfate; (progesterone and testosterone at baseline only)	1033, 1218, 1742, 2028, 2447, 3231
W11	CVD biomarkers - Phase II: strokes after Feb. 2001	Complete	HT Stroke:326 Controls:326 *108 new E+P cases up to July 2002, 174 E alone cases up to March 2004; B+Y1	Citrate .35ml: TFPI activity; TFPI, total; TFPI, free Citrate .65ml: LT_APC; NAPCSR; APC-ETP DNA 1ug: ESR1 -1989; ESR1 IVS1 -1415 C/T; ESR1; GP3A-P1A; ESR2-1730AG; ITGA2807CT; GPIba M145T; ESR1 IVS1 -401 C/T; ESR1 IVS1 -1505 A/G; ESR1 IVS1 -354 A/G; ESR2; ESR1 ex1 +30 T/C; GPIba; Serum .25ml: Insulin; Glucose	462, 1114
W12	Prep DNA samples for 2006 BAAs to be awarded in Jan 2007	Complete	OS	DNA 1ug:	
W13	Prep serum, citrate, and EDTA samples for 2006 BAAs to be awarded in Jan 2007	Complete	General population	Serum 1.05ml:	

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W14	CVD biomarkers - Phase I: additional assays	Complete	HT CHD:390 Stroke:270 VTE:220 Controls:880 *B, Y1	Citrate .95ml: Split samples listed below. Citrate .35ml: TFPI, total; TFPI, free; TFPI activity Citrate .65ml: LT_APC; NAPCSR; APC-ETP Serum .25ml: Insulin; Glucose;	866, 972, 1114, 3202, 3271
W15	Vitamin D levels in CaD participants with colorectal cancer or fractures	Complete	CaD Colorectal Cancer:334 Fracture - Hip:360 Fracture - Elbow, Lower humerous:853 Fracture - Spine Only:283 Controls:1830 *Y1; B only if Y1 not available	Serum .2ml: Vit D 25-OH	450, 451, 581, 876, 878, 910, 1121
W18	HT Hormone Pretest	Complete	HT Controls:240 *120 active + 120 placebo; B, Y1	Serum .95ml: Testosterone, bioavail; Estrone (E1); Testosterone; Estradiol, bioavailable; Progesterone; Estradiol (E2); Estradiol, free; SHBG; Testosterone, free; (progesterone and testosterone only on E+P samples)	795, 1218, 2447
W19	WHI HT Proteomic Pilot Study	Complete	HT Controls:200 *100 active, 100 control; B, AV1	Serum .1ml: Proteomics Serum .15ml: Contingency sample (lab to store sample) Serum .3ml: Phase II proteins	843, 921
W20	WHI-EDRN pilot study for the identification of circulating biomarkers for colon cancer in pre-clinical specimens	Complete	OS Colorectal Cancer:100 Controls:120 *Colon cancer cases 6-18 mo after Year 3	EDTA .2ml: Proteomics; Calibration for Wayne State lab. EDTA .55ml: Proteomics	
W22	Vitamin D levels in 6% blood subsample of CaD	Complete	CaD Controls:600 *CaD at AV1 and AV3, about 200 AA, 100 Hispanics, and 300 Caucasians	Serum .25ml: Vit D 25-OH	
W24	Vitamin D and breast cancer in CaD trial	Complete	CaD Breast Cancer:1081 Controls:1081 *Use controls from W15 when possible	Serum .2ml: Vit D 25-OH	470, 876, 878, 910, 1121

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W25	WHI coronary artery calcification study in E-alone (WHI-CACS)	Complete	HT *1150 E-Alone ppts aged 50-59		503, 506, 570, 591, 816, 955, 2645
W26	Food grouping in WHI by FHCRC nutrition shared resource group	Complete	DM		
W27	Nutrition and physical activity assessment study (AS218) lab work	Complete	OS *450 ppts	<p>NPAAS F177 draws+NPAAS F175 draws: 24hr Urine 4ml: 24 hr urine volume, urinary nitrogen g/day, urinary nitrogen g/L</p> <p>NPAAS F175 draws: 24hr Urine 4ml:</p> <p>NPAAS F177 draws+NPAAS F175 draws: DLW Spot Urine 4ml: Fluid; TEE; Nd; DSRATIO; TEE mj/day; No; RCO2-3/5; BMI; Isotope Approval; RQ; Fat-free mass; % Fat; RCO2-4/6; Total Body Water; r-H2O; %Fat; DE-SU3; DE-SU4; DE-SU5; DE-SU6; EE3/5; EE4/6; Fat-free mass; Fluid; H2CONST; Internal check DSRatio; LOT; Nd; No; O18-SU3; O18-SU4; O18-SU5; O18-SU6; O18CONST; RCO2-3/5; RCO2-4/6; TEE-CONRQ RQ Control group (38.1/44.7/17.2 %E from F/C/P); TEE-INTVRQ Intervention (29.8/52.7/17.5 %E from F/C/P); TEE-USRQ RQ assumed general US (34/47/18 %E F/C/P); Total Body Water; r-H2O</p> <p>NPAAS F177 draws+NPAAS F175 draws: EDTA 1.8ml:</p> <p>NPAAS F177 draws+NPAAS F175 draws: Serum 1ml: Carotene, alpha; Tocopherol, gamma; Cholesterol; Retinyl palmitate; Retinol; Lycopene, all trans; Crypt; Tocopherol, alpha; Carotene, beta; Lutein+Zeaxanthin; Lycopene, total</p>	1178, 1385, 1532, 1903, 2600
W28	Medicare claims data linkage	Complete	General population		
W30	Dietary assessment study	Complete	DM *160 ppts for 4DFR analyses, repeat 24 hr recalls, and repeat FFQs		35
W31	4DFR on DM ovarian cancers	Complete	DM Ovarian Cancer:160 *For DM Other Cancer paper		469

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W33	4DFR and DM breast cancer	Complete	DM Breast Cancer:1800 *For DM Breast Cancer paper		448
W34	Extension of WHI stroke genome-wide association study (W-7)	Complete	General population Stroke:2096 Controls:2096	DNA 2ug: SNPs 5.4K	
W35	Full CMS data on all CT and OS participants aged 65 or over	Complete	General population		889, 890, 1217, 1371, 1372, 1373, 1602, 1608, 1623, 1640, 1655, 1657, 1730, 1747, 1765, 1766, 1767, 1839, 1916, 1917, 2087, 2126, 2139, 2140, 2330, 2333, 2360, 2395, 2432, 2469, 2517, 2674, 2717, 2785, 2799, 2803, 2804, 2807, 2827, 2829, 2862, 2885, 2930, 3064, 3065, 3139, 3184, 3203, 3308, 3309, 3334, 3338, 3342
W39	27-hydroxycholesterol in CVD biomarkers (W-6)	Complete	HT CHD:359 Controls:820 *CHD cases from W6-HT CVD Biomarkers	Serum .55ml: Chol, 27-OH	1300
W40	Validation of E-alone proteins in W19-HT proteomics	Complete	HT Controls:100 *100 E-Alone ppts in active treatment arm	Serum .4ml: AHSB; MMP-2; IGFBP-4; IGFBP-6; FIX; VitD Binding; ACE; Nephroblastoma overexpressed; IGFBP-3; IGFBP-1; IGFBP-2; VTNbis; MCAM; TFF3; ICAM-1; FX; IGF-I; CP; KNG1; Protein Z; CCL16	843, 2447
W41	Medications inventory on WHI Extension participants	Complete	General population		
W42	SEER code WHI and ES non-primary cancers	Complete	General population		
W43	Gene sequencing of selected genes in breast cancer and stroke SNP studies (W7 and W34)	Complete	HT E+P Breast Cancer:60 Controls:60 *60 active treatment. 60 placebo	DNA 0ug: Gene seq; Use samples from W7 and W34.	

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W44	Biological validation of E+P effects on the serum proteome and comparison of E+P and E-Along effects (see W19 and W40)	Complete	HT Controls:50 *50 E+P ppts at baseline,AV1	Serum .55ml: MMP-2; CCL18; LYVE1; ANG; ACE; MCSF1; IGFBP-1; VTNbis; TFF3; IGFBP-2; CP; AGTASE; Apolipoprotein F; TNC; XLKD1; PARCq; CAPPT; CSF1; LGALS3BP; LCN2; Nephroblastoma overexpressed; ICAM-1; IGF-I; FX; MCAM; B2M; IGFBP-4; KNG1; RNASE4; Apo D; THBS1	921
W45	Proteomic Colon Cancer Study	Complete	OS Colon cancer:100 Controls:100	Citrate .15ml: LGALS3BP; IGFBP-1; IGFBP-2; CEA; PKM2; SPARC; MMP-2; NID1; ENO1; PPIA; Amyloid Precursor Protein; LRG1; IGFBP-6; MAPRE1; LTF; ADAMTS13; PPBP	
W47	Breast Tumor Tissue Pilot	Complete	DM Breast Cancer - Invasive:504 *504 ppts diagnosed in 1999-2007 eligible, with 248 tissue samples received .		
W51	Transfer of AS62-WHISE blood samples to WHI repository	Complete	General population		
W52	SHARe data clean-up	Complete	General population		
W54	CVD Biomarkers for 2010-2015 (SHARe cohort only)	Complete	General population Controls:12008 *SHARe ppts (12,008)	Serum .25ml: Glucose; CRP; Creatinine; LDLC; Cholesterol; Insulin; HDLC; Trig	1872, 2272, 2404, 2611, 3202, 3204
W57	Extend CVD Biomarker Study using HT Proteomics Study Findings on B2M and IGFBP4	Complete	General population CHD:354 Stroke:341 Controls:695	Citrate .15ml: B2M Citrate .15ml: IGFBP-4	1065
W58	CVD, diabetes, and renal biomarkers in the EA HT Cohort	Complete	HT Controls:10254 *AS39-WHIMS (6061) + M13-GARNET (3015) + subset of HT EA aged 65 and over (279) and under 65 (899)	Serum .25ml: Cholesterol; Creatinine; Trig; Glucose; HDLC; LDLC; Insulin; CRP	2272, 2404, 2611, 2624, 2024, 3202, 3204
W59	Collaborative telomere studies pilot study (Jacques)	Complete	HT Controls:60	DNA .0625ug: TELO-LNDDCT; Baseline DNA 3ug: DNA 1ug: TELO-LNDDCT DNA .0625ug: TELO-LNDDCT; AV1	

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W60	Cardiovascular Disease Biomarkers and Mediation of Hormone Therapy	Dropped	HT CHD:349 Stroke:329 Controls:678 *From W57	Citrate .1ml: IGFBP-2; HPX; IGFBP-6; B2M; Insulin growth factor 2; Stroke Citrate .1ml: ORM1; CFD; GPX3; IGFBP-1; THBS1; CHD	
W61	DNA Extraction of Medical Records Cohort Participants	Complete	General population Controls:12000 *~12,000 Med Records Cohort ppts who need to be extracted. All to be done and billed by 9/30/11		
W63	GWAS on WHIMS and subsample of HT EA women	Complete	HT Controls:5907 *Goal: Have GWAS available on a representative HT EA cohort via GARNET (M13) and W63. GWASed in W63 = Non- GARNET WHIMS (4661) + HT EA ppts aged 65+ (300) and under 65 (946)	DNA 2ug: Illumina Omn iExpress + Exome	1902, 1919, 1920, 1921, 1925, 1926, 1927, 1932, 1943, 2018, 2024, 2035, 2036, 2037, 2041, 2064, 2093, 2101, 2192, 2321, 2408, 2425, 2481, 2486, 2506, 2509, 2524, 2528, 2531, 2570, 2647, 2649, 2653, 2788, 2806, 2841, 2894, 2942, 2984, 3006, 3020, 3052, 3059, 3082, 3086, 3103, 3205, 3219, 3222, 3227, 3235, 3236, 3296, 3324, 3337
W64	Long Life Study (LLS)	Complete	General population Controls:7875 *7875 63+ year old MRC ppts with GWAS and Baseline Biomarkers	Serum Sst .25ml: Creatinine; Insulin; Cholesterol; Trig; Glucose; HDLC; CRP; LDLC Whole 2ml: MCH; MCV; PLT; BASO; MONO; NEUT; Hemoglobin; PDW; NEUT%; IG; HCT; BASO%; RET; EOS%; RDW-CV; MPV; RBC; EOS; WBC; LYMPH; IG%; RET%; MCHC; RDW-SD; MONO%; LYMPH%; CBC: Performed on the whole blood 2 ml EDTA vial within ~30 hours of draw.	2673, 2836, 2977, 3020, 3164, 3181, 3249, 3362
W66	Long Life Study-Phase III Biomarkers and GWAS	Complete	General population Controls:1500 **Ppts are the last 1500 women to became eligible for the Long Life Study. At the time they became eligible, they did not have GWAS and Baseline Biomarkers. This study was funded to generate those data.	DNA 1.5ug: Illumina Omn iExpress + Exome; GWAs + Exome Chip (Illumina Omni Express/Exome - same as W63) Serum .25ml: Insulin; Creatinine; Glucose; HDLC; Cholesterol; LDLC; Baseline Biomarker - same as W54 and W58	2677, 3202, 3227, 3296, 3337

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
W67	WHI and Group Health Linkage Project	Complete	General population		
W68	WHI GWAS Imputation Project	Complete	General population		1927, 2064, 2864, 2910, 2936, 3068, 3069, 3070, 3144
286 ²	OPACH: Objective physical activity and cardiovascular health in women aged 80 and older	Funded	General population *~7060 LLS eligible (W64)		2246, 2367, 2965
422 ²	Cardiovascular biomarkers in WHI Native Americans	Complete	General population Controls:594 *PAGE Native Americans - 594 (same as pull M6-350)	Serum .25ml: LDLC; HDLC; Insulin; Cholesterol; Trig; Glucose; Creatinine; CRP	
M3 ²	NCI Cancer Genetic Markers of Susceptibility (CGEMS) Initiative: Replication Phase	Complete	OS Breast Cancer:2956 Controls:2956 *Caucasians only.	DNA 4ug: SNPs 30K	874, 906, 907, 1104
M4 ²	Whole genome scan for pancreatic cancer risk in the pancreatic cancer cohort consortium (PANSCAN)	Analysis	General population Pancreatic Cancer:283 Controls:283	DNA 2ug: DNA 4ug: GWAS	875, 930, 931, 932, 933, 934, 936, 1075, 1201, 1276, 1530, 1588, 1663, 1808, 2189, 2195, 2365, 2525
M5 ²	SHARe (SNP Health Association Resource) GWAS	Complete	General population Controls:12007 *Blacks, Hispanics who signed Supplemental Consent	DNA 2ug: GWAS	981, 984, 986, 987, 995, 998, 999, 1001, 1006, 1015, 1016, 1018, 1019, 1024, 1050, 1112, 1145, 1157, 1160, 1167, 1176, 1199, 1200, 1256, 1268, 1286, 1299, 1313, 1314, 1316, 1356, 1370, 1401, 1423, 1453, 1459, 1478, 1486, 1552, 1678, 1728, 1784, 1856, 1872, 1881, 1893, 1925, 1954, 2025, 2036, 2064, 2071, 2205, 2243, 2321, 2362, 2401, 2437, 2502, 2510, 2583, 2653, 2687, 2738

Ref #	Title	Status	Study Population	Analytes/Data	Publications (All times)
M6 ²	Population architecture using genomics and epidemiology (PAGE)	Analysis	General population Colorectal Cancer:1436 Endometrial Cancer:1103 CHD:4274 Type 2 Diabetes:4000 Stroke:3455 Ovarian Cancer:703 Cancer of Lung:1751 Melanoma - Skin:1102 Lymphoma, Non Hodgkins:843 Breast Cancer - Invasive:1961 Controls:16000 *~20,000 ppts (cases & controls) every year for 4 years (new set of outcomes each year)	DNA 2ug: SNPs 96 DNA 1ug: Metabochip DNA 2ug: AIMS DNA 2ug: SNPs 384 EKG DNA 2ug: SNPs 384 Ca; year 2	1073, 1170, 1171, 1172, 1194, 1221, 1238, 1239, 1240, 1242, 1245, 1349, 1350, 1351, 1352, 1353, 1380, 1423, 1440, 1606, 1610, 1648, 1689, 1788, 1807, 1871, 1879, 1885, 1922, 1923, 2076, 2077, 2135, 2151, 2175, 2265, 2279, 2284, 2288, 2329
M13 ²	GWAS of hormone treatment and CVD and metabolic outcomes in WHI GWAS of hormone treatment and CVD and metabolic outcomes in WHI GWAS of hormone treatment and CVD and metabolic outcomes in WHI	Complete	HT/OS CHD:520 Type 2 Diabetes:1080 Stroke:351 VTE:313 Controls:2805 *Controls #s include 174 case/control pairs with multiple outcomes, 200 SHARe ppts	DNA 2ug: GWAS; GWAS in HT DNA 1ug: Exome Chip; exome chip (on residual sample from GWAS) DNA 1ug: Fluidigm Array; Phase II Validation in OS	986, 1483, 1486, 1545, 1675, 2036, 2064, 2310, 2321, 2486, 2510, 2524, 2531, 2633, 2653, 2894, 2920, , 3006, 3008
M24 ²	WHI Sequencing Project (WHISP)	Analysis	General population MI:161 Type 2 Diabetes:165 Stroke:770 Controls:1865 *Phase I: BMI/T2D, early MI. Phase II: Stroke, Hypertension, Deeply Phenotyped Reference Group (DPR); Phase III: extra BMI and Stroke; Replication: 8950 samples (stroke+controls 3000; EOMI+Controls 5000; BP hi/lo 950)	DNA 1ug: GWAS; specimen usage #6: Cross validation exome sequencing at CHARGE-S Lab (Houston, I think) DNA 5ug: EXOMIC SEQ DNA 1ug: Exome Chip; Exome Chip DNA 1.05ug: Exomic Sequencing DNA 5ug: Exomic Sequencing DNA 1.5ug: Exome Chip; Exome Chip DNA 5ug: EXOMIC SEQ	1543, 1544, 1545, 1549, 1550, 1551, 1682, 1709, 1736, 1802, 1822, 1829, 1848, 1875, 1924, 1954, 1996, 2020, 2027, 2031, 2036, 2042, 2050, 2066, 2119, 2160, 2161, 2191, 2213, 2236, 2243, 2286, 2310, 2332, 2398, 2486, 2531, 2595, 2618, 2633, 2643, 2856, 2894, 2920, 2957, 2958, 2959

¹ Core studies are conducted using internal WHI Funds included in the Clinical Coordinating Center budget. Studies are developed and monitored by a study-wide Core Resources Working Group. NHLBI conducts additional peer review of proposed uses beyond those specified in the study protocol (certain subsamples) and pilot projects.

² Core initiative studies that are not funded through WHI funds (they are externally funded)